Compliance Certificate By Practicing Company Secretary For The Half Year Ended On March 31, 2017.
Compliance Certificate by Practicing Company Secretary for the half year ended on March 31, 2017.11-04-2017
Compliance Certificate By Practicing Company Secretary For The Half Year Ended On March 31, 2017.
Compliance Certificate by Practicing Company Secretary for the half year ended on March 31, 2017.Statement Of Investor Complaints For The Quarter Ended On March 31, 2017.
Statement of Investor Complaints for the quarter ended on March 31, 2017.Shareholding for the Period Ended March 31, 2017
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click hereZydus announces settlement with Supernus
Cadila Healthcare Ltd (Zydus Cadila), and its subsidiary Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical company in the United States, on Tuesday, announced that they have finalised an...Zydus inks pact with Supernus Pharma to settle patent issue
Cadila Healthcare Ltd (Zydus Cadila), and its subsidiary Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical company in the United States, on Tuesday, announced that they have finalised an...Board approves Dividend
Pursuant to Part A of Schedule III of the SEBI [Listing Obligations and Disclosure Requirements], 2015, we hereby inform that the Board of Directors at their meeting held today approved payment of interim dividend @ of 65% i.e. Rs. 6.5/- per equity share on 3,90,72,089 Equity Shares of Rs. 10/- each of the Company for the Financial Year 20162017....Outcome of Board Meeting
Pursuant to Part A of Schedule III of the SEBI [Listing Obligations and Disclosure Requirements], 2015, we hereby inform that the Board of Directors at their meeting held today approved payment of interim dividend @ of 65% i.e. Rs. 6.5/- per equity share on 3,90,72,089 Equity Shares of Rs. 10/- each of the Company for the Financial Year 20162017. The Board of Directors has fixed March 14, 2017 as the Record Date to ascertain the list of members...Zydus arm gets USFDA nod to sell anti-viral drug
Zydus Pharmaceuticals US's subsidiary Nesher Pharmaceuticals on Monday informed final approval from the US drug regulator USFDA to market Oseltamivir Phosphate Capsules, USP in the US market....Zydus gets US FDA nod to start Phase 2 clinical trials of Saroglitazar Magnesium
Healthcare major Zydus Cadila on Thursday announced having received US drug regulator US Food and Drug Administration (USFDA) approval for the group's plans to initiate a Phase-2 clinical trial of...Investor Presentation
Zydus Wellness Ltd has informed BSE regarding Investor Presentation.